» Articles » PMID: 36351335

NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022

Abstract

Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.

Citing Articles

Trends and Financial Burden of Gastrointestinal Stromal Tumors in the United States: A Comprehensive Analysis of United States Hospitalizations.

Sonaiya S, Patel R, Parikh C, Dahiya D, Yagnik K, Barnechea Alvarado N Gastroenterology Res. 2025; 18(1):12-22.

PMID: 40051888 PMC: 11882225. DOI: 10.14740/gr2009.


Case report: Clinical and molecular features of renal gastrointestinal tumor.

Makker S, Rammal R, Gu P, Dalbagni G, Al-Ahmadie H, Agaram N Front Oncol. 2025; 15:1508600.

PMID: 40018405 PMC: 11865245. DOI: 10.3389/fonc.2025.1508600.


Inflammatory biomarker correlations and prognosis in high-risk gastrointestinal stromal tumor patients: a multicenter retrospective analysis.

Wang T, Qi L, Zhao Y, Ma X, Li T BMC Gastroenterol. 2025; 25(1):119.

PMID: 40011800 PMC: 11863871. DOI: 10.1186/s12876-025-03710-8.


Case report: One case of precise resection of gastric glomus tumor by gastroscopy combined with laparoscopy.

Yang X, Guo Y, Yan X, Xu B, Cui Z, Guo Z Front Oncol. 2025; 14():1501442.

PMID: 39839772 PMC: 11746095. DOI: 10.3389/fonc.2024.1501442.


Interpretable machine learning model based on CT semantic features and radiomics features to preoperatively predict Ki-67 expression in gastrointestinal stromal tumors.

Wang Y, Bai G, Liu Y, Huang M, Chen W, Wang F Sci Rep. 2024; 14(1):29336.

PMID: 39592767 PMC: 11599915. DOI: 10.1038/s41598-024-80978-y.


References
1.
Belinsky M, Rink L, Cai K, Capuzzi S, Hoang Y, Chien J . Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case. BMC Cancer. 2015; 15:887. PMC: 4641358. DOI: 10.1186/s12885-015-1872-y. View

2.
Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M . Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004; 40(5):689-95. DOI: 10.1016/j.ejca.2003.11.025. View

3.
DeMatteo R, Heinrich M, El-Rifai W, Demetri G . Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002; 33(5):466-77. DOI: 10.1053/hupa.2002.124122. View

4.
Schoffski P, Reichardt P, Blay J, Dumez H, Morgan J, Ray-Coquard I . A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol. 2010; 21(10):1990-1998. DOI: 10.1093/annonc/mdq076. View

5.
Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S . Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279(5350):577-80. DOI: 10.1126/science.279.5350.577. View